George W. Sledge, MD, on HR+/HER2– Breast Cancer: Results From the MONARCH 2 Trial

Posted: Monday, June 5, 2017

George W. Sledge, MD, of Stanford University Medical Center, discussed study findings on abemaciclib in combination with fulvestrant in patients with HR-positive/HER2 negative advanced breast cancer who progressed on endocrine therapy.